Travere Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q3 2013 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Travere Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2013 to Q2 2024.
  • Travere Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was -$1.86M, a 189% decline year-over-year.
  • Travere Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $10.7M, a 263% increase year-over-year.
  • Travere Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $12M.
  • Travere Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$11.3M, a 35% increase from 2021.
  • Travere Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$17.5M, a 38.3% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $10.7M -$1.86M -$3.95M -189% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $14.6M $3.47M +$2.59M +293% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $12M $5.71M +$4.42M +343% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $7.61M $3.36M +$4.67M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $2.94M $2.08M +$3.61M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$670K $883K +$10.7M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 -$11.3M $1.29M +$5.21M Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 -$16.6M -$1.31M +$2.57M +66.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$19.1M -$1.53M +$2.12M +58.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$21.2M -$9.79M -$3.78M -63% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$17.5M -$3.92M -$377K -10.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 -$17.1M -$3.89M -$794K -25.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 -$16.3M -$3.65M -$756K -26.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$15.5M -$6.01M -$2.9M -93.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$12.6M -$3.54M -$1.48M -72% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$11.1M -$3.09M -$515K -20% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 -$10.6M -$2.89M -$789K -37.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 -$9.84M -$3.1M -$753K -32.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$9.09M -$2.06M +$410K +16.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$9.5M -$2.58M +$15.9M +86.1% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$25.4M -$2.1M -$1.5M -249% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$23.9M -$2.35M -$2.11M -891% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$21.8M -$2.47M -$6.61M -160% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-24
Q3 2018 -$15.2M -$18.5M -$10.1M -120% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-24
Q2 2018 -$5.11M -$602K +$954K +61.3% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-24
Q1 2018 -$6.06M -$237K -$1.49M -119% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-24
Q4 2017 -$4.57M $4.14M +$10.1M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-26
Q3 2017 -$14.6M -$8.41M -$18.7M -182% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-26
Q2 2017 $4.04M -$1.56M -$11M -117% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-26
Q1 2017 $15M $1.25M +$15.6M Jan 1, 2017 Mar 31, 2017 10-K 2019-02-26
Q4 2016 -$632K -$5.94M -$8.15M -369% Oct 1, 2016 Dec 31, 2016 10-K/A 2018-07-06
Q3 2016 $7.51M $10.3M -$155M -93.8% Jul 1, 2016 Sep 30, 2016 10-K/A 2018-07-06
Q2 2016 $162M $9.42M +$28M Apr 1, 2016 Jun 30, 2016 10-K/A 2018-07-06
Q1 2016 $134M -$14.4M -$22.1M -286% Jan 1, 2016 Mar 31, 2016 10-K/A 2018-07-06
Q4 2015 $156M $2.21M +$12.5M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-01
Q3 2015 $144M $165M +$161M +4141% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-01
Q2 2015 -$17.3M -$18.6M -$45M -170% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-01
Q1 2015 $27.8M $7.74M +$61.3M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-01
Q4 2014 -$33.6M -$10.3M Oct 1, 2014 Dec 31, 2014 10-K 2017-03-01
Q3 2014 $3.89M +$9.63M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-06
Q2 2014 $26.5M Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 -$53.6M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-11
Q3 2013 -$5.74M Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.